Daily Sepsis Research Analysis
Today’s top sepsis research advances include: 1) an interpretable machine-learning model for early prediction of sepsis-induced coagulopathy with external validation and a deployable web app; 2) a multi-omic analysis linking programmed cell death patterns to outcome, yielding a seven-gene prognostic signature and therapeutic leads; and 3) a large ICU cohort identifying risk factors for 28-day mortality in elderly patients with sepsis-associated acute kidney injury, including a notable associatio
Summary
Today’s top sepsis research advances include: 1) an interpretable machine-learning model for early prediction of sepsis-induced coagulopathy with external validation and a deployable web app; 2) a multi-omic analysis linking programmed cell death patterns to outcome, yielding a seven-gene prognostic signature and therapeutic leads; and 3) a large ICU cohort identifying risk factors for 28-day mortality in elderly patients with sepsis-associated acute kidney injury, including a notable association with epinephrine use.
Research Themes
- Interpretable machine learning for early detection of sepsis complications
- Molecular endotyping via programmed cell death for prognostication
- Risk stratification in sepsis-associated acute kidney injury
Selected Articles
1. Early prediction of sepsis-induced coagulopathy in the ICU using interpretable machine learning: a multi-center retrospective cohort study.
Using ICU databases (MIMIC-IV and eICU-CRD), the authors developed and externally validated interpretable machine-learning models to predict sepsis-induced coagulopathy early. They used LASSO, RF-RFE, and Boruta for feature selection, applied 10 algorithms with cross-validation, explained variable effects with SHAP, and deployed a web-based Shiny app.
Impact: It delivers a clinically implementable, externally validated and interpretable model for early SIC detection, addressing a key gap in timely risk stratification.
Clinical Implications: Supports early identification of SIC risk to trigger intensified monitoring, lab confirmation of coagulopathy, and timely consideration of anticoagulation or adjuncts, with a ready-to-use web tool facilitating bedside deployment.
Key Findings
- Among 10,740 MIMIC-IV ICU patients, 2,232 (20.78%) developed sepsis-induced coagulopathy.
- Features were selected via LASSO, RF-RFE, and Boruta; 10 machine-learning models were trained with 5-fold cross-validation.
- The optimal model was interpreted using SHAP to quantify variable contributions and directions.
- External validation in eICU-CRD and deployment as an interactive Shiny web application were completed; the model showed strong predictive ability.
Methodological Strengths
- Multi-center external validation (eICU-CRD) after model development on MIMIC-IV
- Robust feature selection (LASSO, RF-RFE, Boruta) and cross-validation
- Model interpretability using SHAP
- Clinical deployment via a web-based Shiny application
Limitations
- Retrospective design with potential residual confounding
- Performance metrics are not detailed in the abstract
- Generalizability beyond US ICU datasets remains to be tested
- Clinical impact on decision-making and outcomes not prospectively evaluated
Future Directions: Prospective, multi-center implementation studies to test clinical impact; calibration and threshold optimization; evaluation across international cohorts and subgroups for fairness and transportability.
BACKGROUND: Sepsis-induced coagulopathy ( METHODS: Clinical data for model development were retrieved from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database. Feature selection was performed using three distinct algorithms: least absolute shrinkage and selection operator (LASSO) regression, random forest recursive feature elimination (RF-RFE), and the Boruta method. Ten machine learning models underwent training employing 5-fold cross-validation on the training subset, with subsequent evaluation on the validation subset encompassing discrimination, calibration, and clinical utility metrics. The optimal model underwent further interpretability analysis through SHapley Additive exPlanations (SHAP) to elucidate variable contributions and their directional effects. External validation was then conducted using the electronic Intensive Care Unit Collaborative Research Database (eICU-CRD). Finally, the best-performing model was implemented as a web-based Shiny application featuring an interactive interface. RESULTS: Among 10,740 patients in MIMIC-IV, 2,232 (20.78%) developed CONCLUSION: This model demonstrated strong predictive ability and clinical interpretability, enabling early
2. Multi-Dimensional Characterization of Programmed Cell Death Patterns for Prognostic Stratification and Therapeutic Insights in Sepsis.
By profiling 14 programmed cell death pathways in sepsis, the authors defined two immune- and outcome-distinct molecular subtypes and built a seven-gene prognostic signature validated across cohorts. Single-cell and multi-organ transcriptomics clarified cellular heterogeneity and dynamics, and docking suggested active compounds in Simiao Yongan Decoction may target key PCD proteins.
Impact: It integrates multi-omic data to derive a robust prognostic signature and actionable therapeutic hypotheses centered on programmed cell death biology in sepsis.
Clinical Implications: The seven-gene PCD signature enables risk stratification and could guide enrollment and monitoring in immunomodulatory trials; identified PCD targets and SMYAD-linked compounds suggest multi-target adjunctive therapy avenues.
Key Findings
- Fourteen programmed cell death patterns were profiled in sepsis using GSE65682, revealing two molecular clusters with distinct immune landscapes and outcomes.
- Cluster 1 exhibited poorer prognosis compared with the other cluster.
- A seven-gene PCD-related prognostic signature was developed and validated across multiple cohorts.
- Single-cell and multi-organ transcriptomics clarified cellular heterogeneity and temporal dynamics; docking linked SMYAD active compounds to key PCD proteins.
Methodological Strengths
- Multi-cohort development and validation of a prognostic signature
- Integration of bulk, single-cell, and multi-organ transcriptomics
- Biologically grounded endotyping focused on programmed cell death
- Therapeutic hypothesis generation via molecular docking
Limitations
- Reliance on public retrospective datasets; potential batch effects
- Lack of prospective clinical validation and interventional testing
- Molecular docking is in silico and requires experimental confirmation
- Sample sizes per cohort and exact performance metrics are not detailed in the abstract
Future Directions: Prospective validation across diverse ICUs, integration with bedside biomarkers, and preclinical testing of PCD targets and SMYAD-derived compounds to move toward mechanism-guided adjunctive therapy.
BACKGROUND: Sepsis is a complex and heterogeneous syndrome characterized by dysregulated immune responses and multiple forms of programmed cell death (PCD). Comprehensive understanding of the PCD landscape may provide insights into prognosis and therapeutic targets, whereas its role in sepsis is not well-explored. METHODS: Using the microarray dataset for sepsis (GSE65682), we systematically profiled 14 PCD patterns in sepsis and stratified patients into molecular subtypes with distinct immune landscapes and clinical outcomes. PCD-related prognostic signature was developed and validated across multiple cohorts. Single-cell and multi-organ transcriptomic analyses were conducted to elucidate cellular heterogeneity and temporal dynamics. Molecular docking was used to explore interactions between active compounds of Simiao Yongan Decoction (SMYAD) and key PCD-related proteins. RESULTS: Two clusters with differential transcriptional programs and immune infiltration patterns were identified, in which Cluster 1 showed poorer prognosis. We then developed a seven-gene signature ( CONCLUSION: This study delineates the multi-dimensional role of PCD in sepsis, establishes a reliable prognostic model with strong predictive value, and highlights SMYAD as a potential multi-target therapy. These findings provide new avenues for risk stratification and suggest the promise of integrating PCD biology with adjunctive immunomodulatory strategies.
3. Analysis of prognostic risk factors in critically ill elderly patients with sepsis-associated acute kidney injury.
In 3,338 elderly ICU patients with SA-AKI from MIMIC-IV, 28-day mortality was 26.9%. Age ≥76, higher creatinine, elevated urea/creatinine ratio, liver disease, renal replacement therapy, and several vasoactive agents were associated with increased mortality, whereas epinephrine use correlated with lower mortality.
Impact: Large-scale ICU data clarify modifiable and non-modifiable mortality risk factors in elderly SA-AKI and raise a hypothesis about differential effects of vasoactive agents.
Clinical Implications: Supports risk stratification at admission and during ICU care, encourages judicious selection and sequencing of vasoactive agents, and motivates prospective evaluation of epinephrine’s potential benefit.
Key Findings
- Among 3,338 elderly SA-AKI patients, 28-day mortality was 26.9%.
- Independent risk factors included: age ≥76 (HR 1.392), creatinine ≥1.5 mg/dL (HR 1.216), urea/creatinine ratio ≥20 (HR 1.668), liver disease (HR 1.292), renal replacement therapy (HR 1.476).
- Use of norepinephrine (HR 1.624), dobutamine (HR 1.644), dopamine (HR 1.260), and vasopressin (HR 1.708) was associated with higher mortality.
- Epinephrine use was associated with lower mortality (HR 0.553).
Methodological Strengths
- Large sample size from a well-characterized ICU database (MIMIC-IV)
- LASSO for variable selection and multivariable Cox regression for adjusted estimates
- Reporting of HRs with 95% CIs and P values
Limitations
- Retrospective observational design with potential confounding by indication for vasoactive drug use
- Single healthcare system database; external generalizability uncertain
- Causal effects of vasoactive agents cannot be inferred
Future Directions: External validation across health systems, causal inference analyses (e.g., target trial emulation), and prospective studies to evaluate vasopressor strategies in SA-AKI.
BACKGROUND: To investigate the risk factors influencing the prognosis of critically ill elderly patients with sepsis-associated acute kidney injury (SA-AKI). METHODS: This retrospective study analyzed data from the Medical Information Mart for Intensive Care (MIMIC) Ⅳ database collected between 2008 and 2019. A total of 3,338 elderly patients with SA-AKI were included and categorized into a survival group (n = 2,448) and a death group (n = 898) based on 28-day mortality outcomes. Least Absolute Shrinkage and Selection Operator (LASSO) regression was utilized to identify potential predictors, and multivariate Cox regression was employed to analyze independent risk factors associated with 28-day mortality in elderly patients with SA-AKI. RESULTS: The 28-day mortality rate in elderly patients with SA-AKI was 26.9%. Multivariate Cox regression analysis revealed that age ≥ 76 years (Hazard Ratio[HR] = 1.392, 95% Confidence Interval[CI] 1.212-1.598, P < 0.001), creatinine ≥ 1.5 mg/dL (HR = 1.216, 95%CI 1.037-1.427, P = 0.016), urea-to-creatinine ratio (UCR) ≥ 20 (HR = 1.668, 95%CI 1.441-1.931, P < 0.001), liver disease (HR = 1.292, 95%CI 1.059-1.575, P = 0.011), renal replacement therapy (HR = 1.476, 95%CI 1.160-1.879, P = 0.002), use of norepinephrine (HR = 1.624, 95%CI 1.390-1.896, P < 0.001), dobutamine (HR = 1.644, 95%CI 1.225-2.206, P < 0.001), dopamine (HR = 1.260, 95%CI 1.008-1.576, P = 0.042), and vasopressin (HR = 1.708, 95%CI 1.430-2.041, P < 0.001) were significant risk factors for 28-day mortality in elderly patients with SA-AKI. In contrast, epinephrine use was associated with lower mortality (HR = 0.553, 95%CI 0.417-0.734, P < 0.001). CONCLUSIONS: Elderly SA-AKI patients have a high short-term mortality. Advanced age, renal impairment, liver disease, renal replacement therapy, and the use of several vasoactive drugs were associated with poor outcomes, while the potential benefit of epinephrine requires further validation. CLINICAL TRIAL NUMBER: Not applicable.